Sign in
BCRX Stock Price, Chart, Stats & News
BioCryst Pharmaceuticals, Inc.
Save
1.92B
Market cap
–
Current P/E
78.13x
Forward P/E
BCRX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 97.74% |
Operating margin | 38.98% |
Pretax margin | 30.56% |
Net margin | 30.16% |
Effective tax rate | 1.32% |
ROA | 51.32% |
ROE | -76.45% |
D/E | -4.01x |
Interest coverage ratio | 4.32x |
BCRX valuation
P/E | – |
P/S | 2.24x |
P/B | -16.52x |
P/CF | 5.95x |
P/FCF | 5.96x |
P/OCF | 5.95x |
PEG | 0.00x |
EV multiple | 4.47x |
About
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema.
Similar securities
Based on sector and market capitalization
Report issue